Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial
Lorcaserin is a serotonin 2c receptor agonist that promotes weight loss while contributing to the prevention and improvement of type 2 diabetes and improvement of atherogenic lipid profiles, without higher rates of major cardiovascular events. The full spectrum of possible lorcaserin‐induced improve...
Gespeichert in:
| Veröffentlicht in: | Diabetes, obesity & metabolism obesity & metabolism, 2019-06, Vol.21 (6), p.1487-1492 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1492 |
|---|---|
| container_issue | 6 |
| container_start_page | 1487 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 21 |
| creator | Tuccinardi, Dario Farr, Olivia M. Upadhyay, Jagriti Oussaada, Sabrina M. Mathew, Hannah Paschou, Stavroula A. Perakakis, Nikolaos Koniaris, Anastasia Kelesidis, Theodoros Mantzoros, Christos S. |
| description | Lorcaserin is a serotonin 2c receptor agonist that promotes weight loss while contributing to the prevention and improvement of type 2 diabetes and improvement of atherogenic lipid profiles, without higher rates of major cardiovascular events. The full spectrum of possible lorcaserin‐induced improvements in cardiometabolic health remains to be clarified. Thus, we investigated the way in which lorcaserin treatment may alter cardiovascular disease risk, either independently or through changes in body weight. We measured, for the first time, lipid particle quantification, lipid peroxidation, appetite‐regulating hormones and mRNA expression of the 5‐hydroxytryptamine 2c receptor (5‐HT2c receptor). A total of 48 obese participants were enrolled in this six‐month, randomized (1:1), placebo‐controlled, double‐blinded clinical trial. Lorcaserin treatment reduced fat mass (P |
| doi_str_mv | 10.1111/dom.13655 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2220523706</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2220523706</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4285-11259f8336210aa80a6319ce20e4be4e8aa3d25590221be6a42125ccd3cae96a3</originalsourceid><addsrcrecordid>eNp1kU1uFDEQhS0EIiGw4ALIEiukdOKfdk8PuyhAgjQoG1i3ynYNcXC3B9utMKw4AnfhRpyESiZhFy_s0qtXX9kuxl5KcSRpHfs0HkndGfOI7cu2043Uqnt8G6umXwq1x56VciWEaHW_eMr2tFiotjVmn_1ZpeygYA4TrxmhjjhV7tFRXLBwm_yWX2P4elk5TJ5n9LMj3UH2IY1YwaYYHM-hfONrcDXlwomVLBbk4OdYy1t-wkv48ffX7zFN9fKQZyKlMfxEf8g3ERzaRElHyZxivFF9mm1EEm0M1NXRHhxEumKA-Jw9WUMs-OLuPGBfPrz_fHrerC7OPp6erBrXqt40UiqzXPdad0oKgF5Ap-XSoRLYWmyxB9BeGUP_o6TFDlpFFc557QCXHegD9nrH3eT0fcZSh6s054laDkopYZReiI5cb3Yul1MpGdfDJocR8naQYrgZz0BvHW7HQ95Xd8TZjuj_O-_nQYbjneE6RNw-TBreXXzaIf8BRwufxw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2220523706</pqid></control><display><type>article</type><title>Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Tuccinardi, Dario ; Farr, Olivia M. ; Upadhyay, Jagriti ; Oussaada, Sabrina M. ; Mathew, Hannah ; Paschou, Stavroula A. ; Perakakis, Nikolaos ; Koniaris, Anastasia ; Kelesidis, Theodoros ; Mantzoros, Christos S.</creator><creatorcontrib>Tuccinardi, Dario ; Farr, Olivia M. ; Upadhyay, Jagriti ; Oussaada, Sabrina M. ; Mathew, Hannah ; Paschou, Stavroula A. ; Perakakis, Nikolaos ; Koniaris, Anastasia ; Kelesidis, Theodoros ; Mantzoros, Christos S.</creatorcontrib><description><![CDATA[Lorcaserin is a serotonin 2c receptor agonist that promotes weight loss while contributing to the prevention and improvement of type 2 diabetes and improvement of atherogenic lipid profiles, without higher rates of major cardiovascular events. The full spectrum of possible lorcaserin‐induced improvements in cardiometabolic health remains to be clarified. Thus, we investigated the way in which lorcaserin treatment may alter cardiovascular disease risk, either independently or through changes in body weight. We measured, for the first time, lipid particle quantification, lipid peroxidation, appetite‐regulating hormones and mRNA expression of the 5‐hydroxytryptamine 2c receptor (5‐HT2c receptor). A total of 48 obese participants were enrolled in this six‐month, randomized (1:1), placebo‐controlled, double‐blinded clinical trial. Lorcaserin treatment reduced fat mass (P < 0.001), the fatty liver index (P < 0.0001) and energy intake (P < 0.03) without affecting energy expenditure or lean mass. Total low‐density lipoprotein (LDL) (P < 0.04) and small LDL particles (P < 0.03) decreased, while total high‐density lipoprotein (HDL) P < 0.02) increased and heart rate significantly decreased with lorcaserin treatment. No mRNA expression of the 5‐HT2c receptor was observed in peripheral organs. These data suggest that lorcaserin treatment for six months improves cardiometabolic health in obese individuals, acting mainly through the brain.]]></description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.13655</identifier><identifier>PMID: 30724455</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Anti-Obesity Agents - adverse effects ; Anti-Obesity Agents - pharmacology ; Anti-Obesity Agents - therapeutic use ; Appetite ; Benzazepines - adverse effects ; Benzazepines - pharmacology ; Benzazepines - therapeutic use ; Body fat ; Body weight ; Body Weight - drug effects ; Body weight loss ; cardiovascular disease risk ; Cardiovascular diseases ; Clinical trials ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Double-Blind Method ; Double-blind studies ; Energy expenditure ; Energy intake ; Energy Intake - drug effects ; Energy Metabolism - drug effects ; Evidence-based medicine ; Fatty liver ; Female ; Gene expression ; Health risk assessment ; Heart rate ; High density lipoprotein ; Humans ; Lipid peroxidation ; Lipids ; Lipoproteins - blood ; lorcaserin ; Low density lipoprotein ; Male ; Middle Aged ; Obesity ; Obesity - drug therapy ; Risk factors ; Weight control ; weight loss</subject><ispartof>Diabetes, obesity & metabolism, 2019-06, Vol.21 (6), p.1487-1492</ispartof><rights>2019 John Wiley & Sons Ltd</rights><rights>2019 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4285-11259f8336210aa80a6319ce20e4be4e8aa3d25590221be6a42125ccd3cae96a3</citedby><cites>FETCH-LOGICAL-c4285-11259f8336210aa80a6319ce20e4be4e8aa3d25590221be6a42125ccd3cae96a3</cites><orcidid>0000-0002-9139-7159 ; 0000-0002-5182-3432 ; 0000-0002-2319-6603 ; 0000-0003-3755-8158</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdom.13655$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdom.13655$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30724455$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tuccinardi, Dario</creatorcontrib><creatorcontrib>Farr, Olivia M.</creatorcontrib><creatorcontrib>Upadhyay, Jagriti</creatorcontrib><creatorcontrib>Oussaada, Sabrina M.</creatorcontrib><creatorcontrib>Mathew, Hannah</creatorcontrib><creatorcontrib>Paschou, Stavroula A.</creatorcontrib><creatorcontrib>Perakakis, Nikolaos</creatorcontrib><creatorcontrib>Koniaris, Anastasia</creatorcontrib><creatorcontrib>Kelesidis, Theodoros</creatorcontrib><creatorcontrib>Mantzoros, Christos S.</creatorcontrib><title>Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description><![CDATA[Lorcaserin is a serotonin 2c receptor agonist that promotes weight loss while contributing to the prevention and improvement of type 2 diabetes and improvement of atherogenic lipid profiles, without higher rates of major cardiovascular events. The full spectrum of possible lorcaserin‐induced improvements in cardiometabolic health remains to be clarified. Thus, we investigated the way in which lorcaserin treatment may alter cardiovascular disease risk, either independently or through changes in body weight. We measured, for the first time, lipid particle quantification, lipid peroxidation, appetite‐regulating hormones and mRNA expression of the 5‐hydroxytryptamine 2c receptor (5‐HT2c receptor). A total of 48 obese participants were enrolled in this six‐month, randomized (1:1), placebo‐controlled, double‐blinded clinical trial. Lorcaserin treatment reduced fat mass (P < 0.001), the fatty liver index (P < 0.0001) and energy intake (P < 0.03) without affecting energy expenditure or lean mass. Total low‐density lipoprotein (LDL) (P < 0.04) and small LDL particles (P < 0.03) decreased, while total high‐density lipoprotein (HDL) P < 0.02) increased and heart rate significantly decreased with lorcaserin treatment. No mRNA expression of the 5‐HT2c receptor was observed in peripheral organs. These data suggest that lorcaserin treatment for six months improves cardiometabolic health in obese individuals, acting mainly through the brain.]]></description><subject>Anti-Obesity Agents - adverse effects</subject><subject>Anti-Obesity Agents - pharmacology</subject><subject>Anti-Obesity Agents - therapeutic use</subject><subject>Appetite</subject><subject>Benzazepines - adverse effects</subject><subject>Benzazepines - pharmacology</subject><subject>Benzazepines - therapeutic use</subject><subject>Body fat</subject><subject>Body weight</subject><subject>Body Weight - drug effects</subject><subject>Body weight loss</subject><subject>cardiovascular disease risk</subject><subject>Cardiovascular diseases</subject><subject>Clinical trials</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Double-Blind Method</subject><subject>Double-blind studies</subject><subject>Energy expenditure</subject><subject>Energy intake</subject><subject>Energy Intake - drug effects</subject><subject>Energy Metabolism - drug effects</subject><subject>Evidence-based medicine</subject><subject>Fatty liver</subject><subject>Female</subject><subject>Gene expression</subject><subject>Health risk assessment</subject><subject>Heart rate</subject><subject>High density lipoprotein</subject><subject>Humans</subject><subject>Lipid peroxidation</subject><subject>Lipids</subject><subject>Lipoproteins - blood</subject><subject>lorcaserin</subject><subject>Low density lipoprotein</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Obesity - drug therapy</subject><subject>Risk factors</subject><subject>Weight control</subject><subject>weight loss</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1uFDEQhS0EIiGw4ALIEiukdOKfdk8PuyhAgjQoG1i3ynYNcXC3B9utMKw4AnfhRpyESiZhFy_s0qtXX9kuxl5KcSRpHfs0HkndGfOI7cu2043Uqnt8G6umXwq1x56VciWEaHW_eMr2tFiotjVmn_1ZpeygYA4TrxmhjjhV7tFRXLBwm_yWX2P4elk5TJ5n9LMj3UH2IY1YwaYYHM-hfONrcDXlwomVLBbk4OdYy1t-wkv48ffX7zFN9fKQZyKlMfxEf8g3ERzaRElHyZxivFF9mm1EEm0M1NXRHhxEumKA-Jw9WUMs-OLuPGBfPrz_fHrerC7OPp6erBrXqt40UiqzXPdad0oKgF5Ap-XSoRLYWmyxB9BeGUP_o6TFDlpFFc557QCXHegD9nrH3eT0fcZSh6s054laDkopYZReiI5cb3Yul1MpGdfDJocR8naQYrgZz0BvHW7HQ95Xd8TZjuj_O-_nQYbjneE6RNw-TBreXXzaIf8BRwufxw</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Tuccinardi, Dario</creator><creator>Farr, Olivia M.</creator><creator>Upadhyay, Jagriti</creator><creator>Oussaada, Sabrina M.</creator><creator>Mathew, Hannah</creator><creator>Paschou, Stavroula A.</creator><creator>Perakakis, Nikolaos</creator><creator>Koniaris, Anastasia</creator><creator>Kelesidis, Theodoros</creator><creator>Mantzoros, Christos S.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0002-9139-7159</orcidid><orcidid>https://orcid.org/0000-0002-5182-3432</orcidid><orcidid>https://orcid.org/0000-0002-2319-6603</orcidid><orcidid>https://orcid.org/0000-0003-3755-8158</orcidid></search><sort><creationdate>201906</creationdate><title>Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial</title><author>Tuccinardi, Dario ; Farr, Olivia M. ; Upadhyay, Jagriti ; Oussaada, Sabrina M. ; Mathew, Hannah ; Paschou, Stavroula A. ; Perakakis, Nikolaos ; Koniaris, Anastasia ; Kelesidis, Theodoros ; Mantzoros, Christos S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4285-11259f8336210aa80a6319ce20e4be4e8aa3d25590221be6a42125ccd3cae96a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anti-Obesity Agents - adverse effects</topic><topic>Anti-Obesity Agents - pharmacology</topic><topic>Anti-Obesity Agents - therapeutic use</topic><topic>Appetite</topic><topic>Benzazepines - adverse effects</topic><topic>Benzazepines - pharmacology</topic><topic>Benzazepines - therapeutic use</topic><topic>Body fat</topic><topic>Body weight</topic><topic>Body Weight - drug effects</topic><topic>Body weight loss</topic><topic>cardiovascular disease risk</topic><topic>Cardiovascular diseases</topic><topic>Clinical trials</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Double-Blind Method</topic><topic>Double-blind studies</topic><topic>Energy expenditure</topic><topic>Energy intake</topic><topic>Energy Intake - drug effects</topic><topic>Energy Metabolism - drug effects</topic><topic>Evidence-based medicine</topic><topic>Fatty liver</topic><topic>Female</topic><topic>Gene expression</topic><topic>Health risk assessment</topic><topic>Heart rate</topic><topic>High density lipoprotein</topic><topic>Humans</topic><topic>Lipid peroxidation</topic><topic>Lipids</topic><topic>Lipoproteins - blood</topic><topic>lorcaserin</topic><topic>Low density lipoprotein</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Obesity - drug therapy</topic><topic>Risk factors</topic><topic>Weight control</topic><topic>weight loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tuccinardi, Dario</creatorcontrib><creatorcontrib>Farr, Olivia M.</creatorcontrib><creatorcontrib>Upadhyay, Jagriti</creatorcontrib><creatorcontrib>Oussaada, Sabrina M.</creatorcontrib><creatorcontrib>Mathew, Hannah</creatorcontrib><creatorcontrib>Paschou, Stavroula A.</creatorcontrib><creatorcontrib>Perakakis, Nikolaos</creatorcontrib><creatorcontrib>Koniaris, Anastasia</creatorcontrib><creatorcontrib>Kelesidis, Theodoros</creatorcontrib><creatorcontrib>Mantzoros, Christos S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tuccinardi, Dario</au><au>Farr, Olivia M.</au><au>Upadhyay, Jagriti</au><au>Oussaada, Sabrina M.</au><au>Mathew, Hannah</au><au>Paschou, Stavroula A.</au><au>Perakakis, Nikolaos</au><au>Koniaris, Anastasia</au><au>Kelesidis, Theodoros</au><au>Mantzoros, Christos S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2019-06</date><risdate>2019</risdate><volume>21</volume><issue>6</issue><spage>1487</spage><epage>1492</epage><pages>1487-1492</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><abstract><![CDATA[Lorcaserin is a serotonin 2c receptor agonist that promotes weight loss while contributing to the prevention and improvement of type 2 diabetes and improvement of atherogenic lipid profiles, without higher rates of major cardiovascular events. The full spectrum of possible lorcaserin‐induced improvements in cardiometabolic health remains to be clarified. Thus, we investigated the way in which lorcaserin treatment may alter cardiovascular disease risk, either independently or through changes in body weight. We measured, for the first time, lipid particle quantification, lipid peroxidation, appetite‐regulating hormones and mRNA expression of the 5‐hydroxytryptamine 2c receptor (5‐HT2c receptor). A total of 48 obese participants were enrolled in this six‐month, randomized (1:1), placebo‐controlled, double‐blinded clinical trial. Lorcaserin treatment reduced fat mass (P < 0.001), the fatty liver index (P < 0.0001) and energy intake (P < 0.03) without affecting energy expenditure or lean mass. Total low‐density lipoprotein (LDL) (P < 0.04) and small LDL particles (P < 0.03) decreased, while total high‐density lipoprotein (HDL) P < 0.02) increased and heart rate significantly decreased with lorcaserin treatment. No mRNA expression of the 5‐HT2c receptor was observed in peripheral organs. These data suggest that lorcaserin treatment for six months improves cardiometabolic health in obese individuals, acting mainly through the brain.]]></abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>30724455</pmid><doi>10.1111/dom.13655</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-9139-7159</orcidid><orcidid>https://orcid.org/0000-0002-5182-3432</orcidid><orcidid>https://orcid.org/0000-0002-2319-6603</orcidid><orcidid>https://orcid.org/0000-0003-3755-8158</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2019-06, Vol.21 (6), p.1487-1492 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_proquest_journals_2220523706 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Anti-Obesity Agents - adverse effects Anti-Obesity Agents - pharmacology Anti-Obesity Agents - therapeutic use Appetite Benzazepines - adverse effects Benzazepines - pharmacology Benzazepines - therapeutic use Body fat Body weight Body Weight - drug effects Body weight loss cardiovascular disease risk Cardiovascular diseases Clinical trials Diabetes mellitus Diabetes mellitus (non-insulin dependent) Double-Blind Method Double-blind studies Energy expenditure Energy intake Energy Intake - drug effects Energy Metabolism - drug effects Evidence-based medicine Fatty liver Female Gene expression Health risk assessment Heart rate High density lipoprotein Humans Lipid peroxidation Lipids Lipoproteins - blood lorcaserin Low density lipoprotein Male Middle Aged Obesity Obesity - drug therapy Risk factors Weight control weight loss |
| title | Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T21%3A22%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lorcaserin%20treatment%20decreases%20body%20weight%20and%20reduces%20cardiometabolic%20risk%20factors%20in%20obese%20adults:%20A%20six%E2%80%90month,%20randomized,%20placebo%E2%80%90controlled,%20double%E2%80%90blind%20clinical%20trial&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Tuccinardi,%20Dario&rft.date=2019-06&rft.volume=21&rft.issue=6&rft.spage=1487&rft.epage=1492&rft.pages=1487-1492&rft.issn=1462-8902&rft.eissn=1463-1326&rft_id=info:doi/10.1111/dom.13655&rft_dat=%3Cproquest_cross%3E2220523706%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2220523706&rft_id=info:pmid/30724455&rfr_iscdi=true |